Following years of speculation in the marketplace on when Invitrogen would reach beyond chemistry and service offerings and enter the instrument space, the firm this week launched the first two products in a planned series of low-cost, benchtop instruments.
Chairman and CEO Greg Lucier, speaking at the UBS Global Life Sciences Conference in New York this week, also said that the firm’s portfolio review, which could lead to some divestitures, is on track to be completed by the end of the year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.